Hat mitgewirkt an:
-
Analysen zur Everolimus (RAD001) induzierten Resistenz in Nierenzellkarzinom-Zelllinien
-
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
-
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A